Prescription drug · NDA
Bosulif (Bosutinib) NDC 0069-0136
Bosutinib monohydrate 500 mg/1 · Tablet, Film coated · Oral · Pfizer Laboratories Div Pfizer Inc
NDC codes
FDA NDC Directory| Package NDC | 11-digit (billing) | Package | Copy |
|---|---|---|---|
| 0069-0136-01 | 0006901360100069013601 | 30 TABLET, FILM COATED in 1 BOTTLE (0069-0136-01)Marketed from Sep 4, 2012 |
How the 11-digit form is made: The labeler segment has 4 digits, so one leading zero is added to it (4-4-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules
Product information
- Brand name (proprietary)
- Bosulif
- Generic name (nonproprietary)
- bosutinib
- Active ingredients
- Bosutinib monohydrate — 500 mg/1
- Dosage form
- Tablet, Film coated
- Route
- Oral
- Labeler
- Pfizer Laboratories Div Pfizer IncNDC labeler code 0069
- Product type
- Prescription drug
- Marketing category
- NDA — New Drug ApplicationApplication NDA 203341
- Marketing start
- Listing expires
- Other FDA classes
- Bcr-Abl Tyrosine Kinase Inhibitors (Mechanism)
- Identifiers
- Product ID 0069-0136_ca8600d9-46e6-402d-89f9-bc6a156bf751SPL ID ca8600d9-46e6-402d-89f9-bc6a156bf751SPL set ID adc84ad5-a04d-4fee-9ba8-91f7abd928e3RxCUI 1307624, 1307630, 1307633, 1307635, 1987732, 1987734, 2669663, 2669665, 2672326, 2672328UNII 844ZJE6I55UPC 0300691014158, 0300690504308, 0300690193014, 0300690136011, 0300690135014
- Pharmacologic class
- Kinase Inhibitor
Billing references
What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.
- HCPCS codeNo match
No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.
- NDC on a medical claim
N400069013601followed by a unit qualifier and the quantityPackage 00069-0136-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier
Product label
Current FDA label (SPL), effective .
Indications (excerpt from the label)
BOSULIF is indicated for the treatment of: • Adult and pediatric patients 1 year of age and older with chronic phase (CP) Philadelphia chromosome-positive chronic myelogenous leukemia (Ph+ CML), newly-diagnosed or resistant or intolerant to prior therapy [see Clinical Studies ( 14.1 , 14.2 , 14.3 )] . • Adult patients with accelerated phase (AP), or blast phase (BP) Ph+ CML with resistance or intolerance to prior therapy [see Clinical Studies (14.2) ] . BOSULIF is a kinase inhibitor indicated for the treatment of • adult and pediatric patients 1 year of age and older with chronic phase Ph+ chronic myelogenous leukemia (CML), newly-diagnosed or resistant or intolerant to prior therapy. ( 1 ) …
Excerpt only. Read the full label for complete information.
About NDC 0069-0136
- What is NDC 0069-0136?
- 0069-0136 is the product NDC for Bosulif (bosutinib), Bosutinib monohydrate 500 mg/1 tablet, film coated, listed with the FDA by Pfizer Laboratories Div Pfizer Inc. It has 1 package NDC, shown above in 10- and 11-digit form.
- What drug is associated with this NDC?
- Bosulif (Bosutinib).
- What is the active ingredient?
- Bosutinib monohydrate.
- Who is the labeler?
- Pfizer Laboratories Div Pfizer Inc, NDC labeler code 0069. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.
- What other NDCs exist for Bosulif?
- 5 other product NDCs are listed under this name. See all Bosulif NDCs.
- Is there a related HCPCS / J-code?
- Not in Med-Code's curated HCPCS directory. See Billing references above.
Related NDCs: other Bosulif products
Other finished products listed under the same name: strengths, forms and labelers.
| Product | Strength | Form · route | Labeler | Product NDC | Package NDCs (11-digit) |
|---|---|---|---|---|---|
| Bosulifbosutinib | Bosutinib monohydrate 50 mg/1 | CapsuleOral | Pfizer Laboratories Div Pfizer Inc | 0069-0504 | 00069-0504-30 |
| Bosulifbosutinib | Bosutinib monohydrate 100 mg/1 | CapsuleOral | Pfizer Laboratories Div Pfizer Inc | 0069-1014 | 00069-1014-15 |
| Bosulifbosutinib | Bosutinib monohydrate 400 mg/1 | Tablet, Film coatedOral | Pfizer Laboratories Div Pfizer Inc | 0069-0193 | 00069-0193-01 |
| Bosulifbosutinib | Bosutinib monohydrate 100 mg/1 | Tablet, Film coatedOral | Pfizer Laboratories Div Pfizer Inc | 0069-0135 | 00069-0135-01 |
| Bosulifbosutinib | Bosutinib monohydrate 400 mg/1 | Tablet, Film coatedOral | U.S. Pharmaceuticals | 63539-193 | 63539-0193-30 |
Other NDCs under NDA 203341
Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.
| Product | Strength | Form · route | Labeler | Product NDC |
|---|---|---|---|---|
| Bosulifbosutinib | Bosutinib monohydrate 100 mg/1 | Tablet, Film coatedOral | Pfizer Laboratories Div Pfizer Inc | 0069-0135 |
| Bosulifbosutinib | Bosutinib monohydrate 400 mg/1 | Tablet, Film coatedOral | Pfizer Laboratories Div Pfizer Inc | 0069-0193 |
| Bosulifbosutinib | Bosutinib monohydrate 400 mg/1 | Tablet, Film coatedOral | U.S. Pharmaceuticals | 63539-193 |